ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/proteasome-inhibitor
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/proteasome-inhibitor
17
trial(s) found.
NCT06615479
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of BMS-986393, a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma (
CA088-1007
)
autologous CAR-T cell therapy,GPRC5D-targeting
immunomodulatory imide drug
+ proteasome inhibitor
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06577025
Haem
Phase 2
Recruiting
A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Combination With Daratumumab SC (Tal-D) and Teclistamab SC in Combination With Daratumumab SC (Tec-D) Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Participants With Standard-risk Newly Diagnosed Multiple Myeloma (
aMMbition
)
anti-CD38 monoclonal antibody
autologous CAR-T-cell therapy,BCMA-targeting
bispecific T-cell engager,BCMA-targeting
bispecific T-cell engager,GPRC5D-targeting
glucocorticoid
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
NCT06413498
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma (
iMMagine-3
)
Bortezomib
Carfilzomib
Cyclophosphamide
Daratumumab
Dexamethasone
Fludarabine
Pomalidomide
alkylating agent
anti-CD38 monoclonal antibody
antimetabolite
cancer therapy
cancer therapy,CD38-targeting
cancer therapy,cereblon-targeting
cancer therapy,proteasome-targeting
cereblon modulator
cytotoxic chemotherapy
glucocorticoid
immuno-oncology therapy,CD38-targeting
immunomodulatory imide drug
proteasome inhibitor
+ proteasome inhibitor
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3121 - Richmond - Epworth Freemasons Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06208150
Haem
Phase 3
Recruiting
A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide (
MonumenTAL-6
)
anti-CS1 monoclonal antibody
bispecific T-cell engager,BCMA-targeting
bispecific T-cell engager,GPRC5D-targeting
glucocorticoid
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2500 - Wollongong - Wollongong Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6005 - West Perth - Perth Blood Institute
NCT06158841
Haem
Phase 3
Recruiting
A Phase 3, Multicenter, Randomized, Open Label Study of Etentamig Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study) (
CERVINO
)
ABBV-383
Bortezomib
Carfilzomib
Dexamethasone
Elotuzumab
Pomalidomide
Selinexor
XPO1 inhibitor
anti-CS1 monoclonal antibody
bispecific T-cell engager,BCMA-targeting
cancer therapy
cancer therapy,BCMA-targeting
cancer therapy,CS1-targeting
cancer therapy,XPO1-targeting
cancer therapy,cereblon-targeting
cancer therapy,proteasome-targeting
cereblon modulator
glucocorticoid
immuno-oncology therapy,BCMA-targeting
immuno-oncology therapy,CS1-targeting
immunomodulatory imide drug
proteasome inhibitor
therapeutic modality,bispecific T-cell engager
therapeutic modality,bispecific antibody
+ proteasome inhibitor
Multiple myeloma
NSW
2170 - Liverpool - Liverpool Hospital
2217 - Kogarah - St George Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT06152575
Haem
Phase 3
Recruiting
A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE (PVd) OR CARFILZOMIB, DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTI-CD38 DIRECTED THERAPY (
C1071032
)
anti-CS1 monoclonal antibody
bispecific T-cell engager,BCMA-targeting
glucocorticoid
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
NSW
2139 - Concord - Concord Repatriation General Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3066 - Epping - Northern Hospital
QLD
4575 - Birtinya - Sunshine Coast University Hospital
NCT05704049
Haem
Phase 2
Recruiting
A Randomized, Phase 2, Open Label Study Evaluating Subcutaneous Administration of Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) (
IZALCO
)
anti-CD38 monoclonal antibody
glucocorticoid
proteasome inhibitor
Multiple myeloma
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
NCT05572515
Haem
Phase 3
Recruiting
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide (
MajesTEC-9
)
bispecific T-cell engager,BCMA-targeting
glucocorticoid
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
NCT05552976
Haem
Phase 3
Recruiting
A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM):
SUCCESSOR-2
cereblon E3 ligase modulator
glucocorticoid
proteasome inhibitor
Multiple myeloma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital (WITHDRAWN)
NCT05519085
Haem
Phase 3
Recruiting
A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM):
SUCCESSOR-1
cereblon E3 ligase modulator
glucocorticoid
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
NSW
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2500 - Wollongong - Wollongong Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.9016 - Dunedin - Dunedin Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (WITHDRAWN)
NCT05257083
Haem
Phase 3
Recruiting
A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (
CARTITUDE-6
)
anti-CD38 monoclonal antibody
autologous CAR-T-cell therapy,BCMA-targeting
glucocorticoid
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT04975997
Haem
Phase 3
Recruiting
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) (
EXCALIBER-RRMM
)
CELMoD agent
anti-CD38 monoclonal antibody
glucocorticoid
proteasome inhibitor
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
ACT
2605 - Garran - The Canberra Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6005 - West Perth - Sir Charles Gairdner Hospital / Western Heamatology and Oncology Clinics
6150 - Murdoch - Fiona Stanley Hospital
NCT04973605
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) (
BGB-11417-105
)
anti-CD38 monoclonal antibody
glucocorticoid
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
ACT
2605 - Garran - The Canberra Hospital
NSW
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
WA
6000 - Perth - Royal Perth Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT03590171
Paed
Phase 2
Recruiting
International Study for Treatment of High Risk Childhood Relapsed ALL 2010 A Randomized Phase II Study Conducted by the Resistant Disease Committee of the International Berlin, Frankfurt, Münster (BFM) Study Group (
IntReALL-HR-2010
)
Bortezomib
cancer therapy
cancer therapy,proteasome-targeting
proteasome inhibitor
+ proteasome inhibitor
Acute lymphoblastic leukaemia
VIC
3168 - Clayton - Monash Medical Centre
ACTRN12624001468516
Haem
Phase 2
Not yet recruiting
A phase 2 study of the feasibility and efficacy of at home patient administered subcutaneous daratumumab in patients with relapsed multiple myeloma (
Dara@Home
)
anti-CD38 monoclonal antibody
+ proteasome inhibitor
Multiple myeloma
ACTRN12622001366741
Haem
Phase 2
Recruiting
Investigating the efficacy of Risk Directed front-line therapy for Multiple Myeloma incorporating Selinexor: The
RIDDLE-M-X
trial
XPO1 inhibitor
+ proteasome inhibitor
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2640 - Albury - Border Medical Oncology Research Unit
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
ACTRN12621001458820
Haem
Phase 1
Not yet recruiting
Phase I Clinical Trial to Determine Dosing Schedule of Hydroxychloroquine in Participants with Multiple Myeloma and Partial Response or Less to Carfilzomib (
CHARMM
)
anti-malarial agent
proteasome inhibitor
Cancer
Multiple myeloma
NSW
2170 - Liverpool - Liverpool Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (15)
Not yet recruiting (2)
Recruitment Country and State
VIC (15)
NSW (14)
QLD (8)
WA (8)
SA (5)
NZ (2)
ACT (2)
Phase
Phase 1 (1)
Phase 1 / Phase 2 (1)
Phase 2 (5)
Phase 3 (10)
Trial Type
Haem (16)
Paed (1)
Cancer Therapy Class
proteasome
100%
cereblon
71%
CD38
47%
BCMA
35%
GPRC5D
18%
CS1
18%
XPO1
12%
Bcl2
6%
Facility
3065 - Fitzroy - St Vincent's Hospital Melbourne (8)
3004 - Melbourne, Southbank - Alfred Health (7)
2050 - Camperdown - Chris O'Brien Lifehouse (6)
3168 - Clayton - Monash Medical Centre (5)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (5)
2170 - Liverpool - Liverpool Hospital (4)
6150 - Murdoch - Fiona Stanley Hospital (4)
3128 - Box Hill - Box Hill Hospital - Eastern Health (4)
4575 - Birtinya - Sunshine Coast University Hospital (4)
3000 - Melbourne - Peter MacCallum Cancer Centre (3)
4102 - Woolloongabba - Princess Alexandra Hospital (3)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (3)
2500 - Wollongong - Wollongong Hospital (3)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (3)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (2)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (2)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (2)
3066 - Epping - Northern Hospital (2)
3002 - East Melbourne - Epworth Freemasons (2)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (2)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (2)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (2)
2605 - Garran - The Canberra Hospital (2)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (2)
3121 - Richmond - Epworth Freemasons Hospital (1)
4215 - Southport - Gold Coast University Hospital (1)
6005 - West Perth - Perth Blood Institute (1)
2217 - Kogarah - St George Hospital (1)
2139 - Concord - Concord Repatriation General Hospital (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (1)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (1)
7000 - Hobart - Royal Hobart Hospital (1)
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit (1)
NZ.9016 - Dunedin - Dunedin Hospital (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
5042 - Bedford Park - Flinders Medical Centre (1)
6005 - West Perth - Sir Charles Gairdner Hospital / Western Heamatology and Oncology Clinics (1)
6000 - Perth - Royal Perth Hospital (1)
2640 - Albury - Border Medical Oncology Research Unit (1)
Cancer Type
Cancer
Haematological malignancy
Multiple myeloma
Plasma cell disorder
Acute lymphoblastic leukaemia
Leukaemia
Lymphoid leukaemia
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy